This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

William D. Dupont, PhD; David L. Page, MD
Nashville, Tenn

Arch Intern Med. 1992;152(5):1090-1093.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply. —

We have a number of technical concerns about the article by Steinberg et al¹ that lead us to believe that their confidence interval for breast cancer risk after 15 years of estrogen replacement therapy (ERT) is too narrow. Steinberg et al¹ fit a simple exponential model with a single slope parameter to complex data from multiple studies. They obtain a separate slope parameter estimate from each study and then take a weighted average of these estimates to determine the duration-risk effect from all studies. Unfortunately, most of the studies that have looked at the duration effect have followed up women for less than 10 years, and there have been only three studies^2-4 that have observed substantial numbers of patients who have taken ERT for more than 15 years. Thus, by taking a weighted slope estimate from all studies, regardless of their duration, they are extrapolating . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?